A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer

BACKGROUND: The mutation in KRAS exon 2 is a validated biomarker of resistance to anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer (mCRC). Several reports have confirmed associations of other RAS mutations with resistance to anti-EGFR therapy. However, the impact...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:BMC Cancer
Autores principales: Kawazoe, Akihito, Shitara, Kohei, Fukuoka, Shota, Kuboki, Yasutoshi, Bando, Hideaki, Okamoto, Wataru, Kojima, Takashi, Fuse, Nozomu, Yamanaka, Takeharu, Doi, Toshihiko, Ohtsu, Atsushi, Yoshino, Takayuki
Formato: Artigo
Lenguaje:Inglês
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4393591/
https://ncbi.nlm.nih.gov/pubmed/25886136
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-015-1276-z
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares